Celontin Capsule
Product Images NDC 0071-0525

4 FDA label images from Parke-davis Div Of Pfizer Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Celontin (NDC 0071-0525). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Parke-davis Div Of Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecular Structure.jpg (Molecular Structure)

Molecular Structure.jpg (Molecular Structure)
Chemical structure of methsuximide, the active ingredient in Celontin 300 mg capsules. The diagram shows the molecular arrangement of atoms including a succinimide ring with methyl and phenyl substitutions.*
FDA Label Image

Logo 1.jpg (Logo 01)

FDA Label Image
FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

Principal Display Panel (300 mg Capsule Bottle Label)
Celontin 300 mg capsules, oral, containing methsuximide, distributed by Parke-Davis Division of Pfizer Inc. The label includes storage instructions, dosage warnings, and a package count of 100 capsules. The product NDC is 0071-0525-24. Additional identifiers include lot number, expiration date, serial number, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.